DPT invests $15m in Texas manufacturing centre

By Gareth Macdonald

- Last updated on GMT

Related tags: Investment

DPT Laboratories has added bulk production and packaging capacity at its liquid and semi-solids plant in San Antonio, Texas in a continuation of its recent manufacturing reorganisation.

The US contract development and manufacturing organisation (CDMO) invested $15m (€12m) in the facility, ​adding two bulk production areas and three filling lines.

The expansion project also added a clinical-scale pressurized metered dose inhalers (pMDI) production unit to compliment the existing 5547 sq m of dedicated large-scale manufacturing space already at the facility.

The San Antonio unit is one of three newly​ restructured “Centers of Excellence” ​that DPT established earlier this year in a bid to increase the efficiency of its manufacturing operations.

The CDMO’s sterile and specialty products manufacturing unit, in Lakewood, New Jersey, was given a $30m transformation in April​. That project added microbiology laboratory, sterility and endotoxin testing capacity as well as environmental monitoring capabilities to existing manufacturing capacity.

A DPT spokesman Outsourcing-pharma spoke with when the "Centers of Excellence" project was announced explained that the wider manufacturing reorganisation had been motivated by a “focus on specific client needs and the ability to provide customer service from personnel who are experts within a specialized area.”

This sentiment was echoed in a statement accompanying news of the San Antonio expansion by company VP of operations Mark Fite who said: “As DPT continues to grow, we always seek opportunities to increase efficiencies​.”

Fite added that: “This investment provides us with expanded capacity, capabilities and ultimately more flexibility for our customers​” that will enable “high-speed, cost-effective manufacturing runs.”

The company has not said whether it plans to undertake a similar capacity expansion at its R&D centre, also in San Antonio, although such a move would clearly be in keeping with its recent strategy.

Related news

Show more

Related product

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us


View more